Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

Volume: 5, Issue: 1, Pages: 9649 - 9649
Published: Apr 16, 2015
Abstract
Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. Aβ capture by these clinical antibodies is explained here with the first reported mid-region Aβ-anti-Aβ complex crystal structure. Solanezumab accommodates a large Aβ epitope (960 A2 buried interface over residues 16 to...
Paper Details
Title
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
Published Date
Apr 16, 2015
Volume
5
Issue
1
Pages
9649 - 9649
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.